long intergenic non-protein coding RNA 1422Genealiases: []
Q-omics provides the consensus-scored LINC01422 profile across patient tissues and cancer cell-line models. LINC01422 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01422 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, LINC01422 RNA expression shows 19,108 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where LINC01422 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01422 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01422 survival associations across molecular data types. LINC01422 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01422 RNA expression–survival associations across cancer types. High LINC01422 expression shows unfavorable associations in KIRC, but favorable associations in HNSC, READ, BLCA, CESC and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01422 RNA expression.
This table summarizes LINC01422 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01422. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01422 shows lower tumor expression in COAD, BRCA, UCEC, LUSC and THCA and higher tumor expression in KIRC. The COAD box plot shows higher LINC01422 RNA expression in normal versus tumor tissue (log2 FC = −0.069, t-test p = .002).
This table shows molecular features associated with LINC01422 in patient tissues and cancer cell lines. In patient samples, LINC01422 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
